



# به نام خرد و شرف

امید روشنائی در تیرگی ها هم هست.

به هشتمین سمینار جامع سرطان شناسی استان گیلان (GCOC 8)  
خوش آمدید.





Panel subject: 2024/02/22

## Nasopharynx Cancer



گرداننده پانل: آقای دکتر فرزین دهسرا (متخصص رادیوآنکولوژی)

اعضای پانل:



آقای دکتر حسین یحیی زاده  
(متخصص رادیوآنکولوژی)




آقای دکتر احمد عامری  
(متخصص رادیوآنکولوژی)



آقای دکتر پیمان دبیرمقدم  
(متخصص ENT)




آقای دکتر کیوان آقازاده  
(متخصص ENT)



- **H:** A 47 year old male who is an electronic engineer has come to us with the complaint of painless mass in Rt upper neck, nasal speech and bilateral aural problems since 4 months ago and recently diplopia. What other Qs should we ask?
- **HH:** smokes and drinks seldom, Married, Has 2 small children.



- **PMH:** DM 2, mild, since 4 years ago
- FH: his uncle has had rectal CA , now is ok.
- **P:** a 3\*2 cm non tender and firm mass in Rt upper neck + 6<sup>th</sup> left cranial nerve palsy
- What should we do now?  
(WSWDN?)





- **EUA:** A 5\*4 cm NP mass, biopsy done
- **Patho report:** NP SCC, grade 2
- What should ENT specialist do now?



- He refers the patient to a radiation oncologist.

- What should a RO do now?

- Stage?



- **FNCAP CT-scan:** NP enhancing mass, Lt PN sinus bone destruction. 45\*43\*34 mm, bilateral neck LAPs, the largest: Rt side 32\*25\*25 mm. Lung: NI, Liver: NI.
- **Brain MRI +/- GAD is needed?**
- Before initiating chemotherapy and radiotherapy, complete dental exam is needed.








# NCCN Guidelines Version 2.2024

## Cancer of the Nasopharynx

### WORKUP

- H&P<sup>a,b</sup> including a complete head and neck exam; mirror examination as clinically indicated
- Nasopharyngeal fiberoptic examination
- Biopsy of primary site or FNA of the neck<sup>c</sup>
- MRI with and without contrast of skull base to clavicle ± CT of skull base/neck with contrast to evaluate skull base erosion
- Imaging for distant metastases with FDG-PET/CT and/or chest CT with contrast<sup>d</sup>
- Consider Epstein-Barr virus (EBV)/DNA testing<sup>e</sup>
- As clinically indicated:
  - Dental/prosthetic evaluation<sup>f</sup>
  - Nutrition, speech and swallowing evaluations/therapy<sup>g</sup>
  - Audiogram
  - Consider ophthalmologic and endocrine evaluation
  - Smoking cessation counseling<sup>a</sup>
  - Fertility/reproductive counseling<sup>h</sup>
  - Screening for hepatitis B
- Multidisciplinary consultation as clinically indicated

### CLINICAL STAGING





**Table 2**

**American Joint Committee on Cancer (AJCC)**

**TNM Staging System for the Nasopharynx (8th ed., 2017)**

(The following types of cancer are not included: Mucosal melanoma, lymphoma, sarcoma of the soft tissue, bone and cartilage.)

### Primary Tumor (T)

- TX** Primary tumor cannot be assessed
- T0** No tumor identified, but EBV-positive cervical node(s) involvement
- Tis** Carcinoma *in situ*
- T1** Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement
- T2** Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles)
- T3** Tumor with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses
- T4** Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/ or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle

### Regional Lymph Nodes (N)

- NX** Regional lymph nodes cannot be assessed
- N0** No regional lymph node metastasis
- N1** Unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- N2** Bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- N3** Unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage

### Distant Metastasis (M)

- M0** No distant metastasis
- M1** Distant metastasis

### Histologic Grade (G)


A grading system is not used for NPCs.

### Anatomic Stage/Prognostic Groups

<b>Stage 0</b>	Tis	N0	M0
<b>Stage I</b>	T1	N0	M0
<b>Stage II</b>	T0,T1	N1	M0
	T2	N0,N1	M0
<b>Stage III</b>	T0,T1,T2	N2	M0
	T3	N0,N1,N2	M0
<b>Stage IVA</b>	T4	N0,N1,N2	M0
	Any T	N3	M0
<b>Stage IVB</b>	Any T	Any N	M1

**Stage: T4 N2 M0 (4A)**

- **EBV DNA copy number?**
- **Tx?**






### CLINICAL STAGING

### TREATMENT OF PRIMARY AND NECK<sup>i</sup>

### FOLLOW-UP



- 3 ChT (TPF), Then EBRT (7020 cGy/39 F) + concurrent weekly cisplatin 50 mg/W.
- His symptoms improved significantly after 3 courses of TPF.





- 6W after completion of RT, he was referred again to head and neck oncosurgeon to be examined.
- The mass size has decreased significantly in exam. 1 \* 1 cm in NP, taking biopsy needed?
- FU?
- PET, CT or MRI?




- 2m after completion of RT, FNC CT-scan requested:
- The mass size has decreased significantly 1 \* 1 cm in NP, enhancing mass. neck: NI.


- WSWDN?



## FOLLOW-UP RECOMMENDATIONS POST SYSTEMIC THERAPY/RT OR RT NECK EVALUATION<sup>h</sup>



**I have a dream, dream of freedom, freedom for all my countrymates ...**



**Thank you for your attention**